OVERVIEW ·     TRACK
RECORD
·     BENEFITS ·     FAQs  ·    WHAT'S NEXT ·      HOW WE
PICK STOCKS
·       SUBSCRIBE ·      PENNYSTOCKSTM
NEWSLETTER  
Facebook
Visit and like us:

Share:
Forbes Directory - Best of the Web
Best of the Web
(Small Caps)
Barron's > read review
As Featured:
*BARRON's
*CNNfn.com
*BusinessWeek Online
*Wired News
*C/NET
*Barron's Electronic
Edition


*Home
*Links
*Sitemap

Ads From Google

The only penny stock site recommended in Barron's and by Forbes.

Online since 1996, we pick stocks trading at under $5.00 that are listed on the NYSE, NASDAQ, and AMEX.

To learn what this site is really about, we urge you to visit the Overview and Track Record pages. However, before doing so, take a glance at a few of our all-time winners. Of course, these are the subsequent gains reached once they hit our target prices and we closed the positions, but it is fun to ponder. The first price was the initial recommendation, followed by the subsequent high, and the eventual ultimate percentage gain. No doubt, you will recognize most of these companies.

Netegrity $2.18 to $73.20 3487%
(acquired by IBM)
Inhibitex $2.35 to $24.08 925%
(acquired by BristolMyersSquibb)
Cellstar $1.44 to $13.50 837%
Iomega $3.25 to $13.90 328%
Nanophase $3.75 to $16.75 347%
Immunomedics $1.44 to $29.12 1922%
Total Renal Care $3.12 to $26.95 741%
Voxware $ .90 to $10.31 1046%
Corvas $3.00 to $23.25 675%
Cytogen $2.12 to $17.50 725%
Verilink $3.00 to $14.62 387%
GeneLabs $2.31 to $10.72 364%

"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"

— B.K. (Contractor in Saudi Arabia)

See what our subscribers have to say...

70% FOR GAINS!
70% OF OUR CLOSED POSITIONS
ARE FOR GAINS OF 50%
OR GREATER (see TRACK RECORD)
RIGHT NOW!
IN THE CURRENT NEWSLETTER!

SEVERAL ANALYSTS rate this biotech a "BUY" as it develops vaccines for various ailments and has alliances with Novartis, Merial, and the U.S. government. This is our second time with this one as the first go-around worked pretty well; trading at the lower end of its 52-week range at around $2.08.

THREE ANALYSTS rate this biotech a "STRONG BUY" or a "BUY" as it develops therapies to treat diseases such as Gaucher, Crohns, and Fabrey, along with about half a dozen others and has a licensing agreement with Teva Pharmaceuticals; trading near its 52-week low at around $2.60.

Hold on for the wild rides!
See "What's Next"
Disclaimer: Penny stock trading involves substantial risk, so always research every recommendation before trading, consult with licensed professionals before trading, and always trade with caution. The recommendations listed in the Newsletter are only for investment ideas and are not solicitations to purchase equities. For more extensive details, view the Privacy Policy and Disclaimer page.

Ads From Google